151 related articles for article (PubMed ID: 20528879)
1. Vascular PAR-1: activity and antagonism.
Lang NN; Guðmundsdóttir IJ; Newby DE
Cardiovasc Ther; 2011 Dec; 29(6):349-61. PubMed ID: 20528879
[TBL] [Abstract][Full Text] [Related]
2. Discovery of an orally available PAR-1 antagonist as a novel antiplatelet agent.
Lee S
Arch Pharm Res; 2011 Apr; 34(4):515-7. PubMed ID: 21544715
[TBL] [Abstract][Full Text] [Related]
3. Platelet protease-activated receptor antagonism in cardiovascular medicine.
Wiisanen ME; Moliterno DJ
Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
[TBL] [Abstract][Full Text] [Related]
4. Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.
Macaulay TE; Allen C; Ziada KM
Expert Opin Pharmacother; 2010 Apr; 11(6):1015-22. PubMed ID: 20307225
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
Morrow DA; Scirica BM; Fox KA; Berman G; Strony J; Veltri E; Bonaca MP; Fish P; McCabe CH; Braunwald E;
Am Heart J; 2009 Sep; 158(3):335-341.e3. PubMed ID: 19699854
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1.
Tsopanoglou NE; Maragoudakis ME
Semin Thromb Hemost; 2007 Oct; 33(7):680-7. PubMed ID: 18000795
[TBL] [Abstract][Full Text] [Related]
7. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis.
Oestreich J
Curr Opin Investig Drugs; 2009 Sep; 10(9):988-96. PubMed ID: 19705342
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action and clinical development of platelet thrombin receptor antagonists.
Ueno M; Ferreiro JL; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1191-200. PubMed ID: 20670195
[TBL] [Abstract][Full Text] [Related]
9. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
White HD
Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
[TBL] [Abstract][Full Text] [Related]
10. Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans.
Gudmundsdóttir IJ; Lang NN; Boon NA; Ludlam CA; Webb DJ; Fox KA; Newby DE
J Am Coll Cardiol; 2008 May; 51(18):1749-56. PubMed ID: 18452780
[TBL] [Abstract][Full Text] [Related]
11. Novel anti-platelet agents: focus on thrombin receptor antagonists.
de Souza Brito F; Tricoci P
J Cardiovasc Transl Res; 2013 Jun; 6(3):415-24. PubMed ID: 23435863
[TBL] [Abstract][Full Text] [Related]
12. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
Tricoci P; Huang Z; Held C; Moliterno DJ; Armstrong PW; Van de Werf F; White HD; Aylward PE; Wallentin L; Chen E; Lokhnygina Y; Pei J; Leonardi S; Rorick TL; Kilian AM; Jennings LH; Ambrosio G; Bode C; Cequier A; Cornel JH; Diaz R; Erkan A; Huber K; Hudson MP; Jiang L; Jukema JW; Lewis BS; Lincoff AM; Montalescot G; Nicolau JC; Ogawa H; Pfisterer M; Prieto JC; Ruzyllo W; Sinnaeve PR; Storey RF; Valgimigli M; Whellan DJ; Widimsky P; Strony J; Harrington RA; Mahaffey KW;
N Engl J Med; 2012 Jan; 366(1):20-33. PubMed ID: 22077816
[TBL] [Abstract][Full Text] [Related]
13. PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.
Leonardi S; Becker RC
Handb Exp Pharmacol; 2012; (210):239-60. PubMed ID: 22918734
[TBL] [Abstract][Full Text] [Related]
14. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
Gurbel PA; Jeong YH; Tantry US
Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
[TBL] [Abstract][Full Text] [Related]
15. G-protein-coupled receptors as signaling targets for antiplatelet therapy.
Smyth SS; Woulfe DS; Weitz JI; Gachet C; Conley PB; Goodman SG; Roe MT; Kuliopulos A; Moliterno DJ; French PA; Steinhubl SR; Becker RC;
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):449-57. PubMed ID: 19023091
[TBL] [Abstract][Full Text] [Related]
16. Challenges and promises of developing thrombin receptor antagonists.
Yang J; Xu K; Seiffert D
Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):162-70. PubMed ID: 20874673
[TBL] [Abstract][Full Text] [Related]
17. Protease-Activated Receptor-1 Antagonists Post-Percutaneous Coronary Intervention.
Tricoci P
Interv Cardiol Clin; 2017 Jan; 6(1):57-66. PubMed ID: 27886823
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
Jennings LK
Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
[TBL] [Abstract][Full Text] [Related]
19. Protease-activated receptor-1 antagonists: focus on SCH 530348.
Sugunaraj JP; Mehta V; Kalra A; Sukhija R; Palaniswamy C
Am J Ther; 2012 Nov; 19(6):465-9. PubMed ID: 21248619
[TBL] [Abstract][Full Text] [Related]
20. Coagulation cascade proteases and tissue fibrosis.
Chambers RC; Laurent GJ
Biochem Soc Trans; 2002 Apr; 30(2):194-200. PubMed ID: 12023850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
